AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Ventricular Tachycardia:A Registry Study

Recruitingn/aAges 18 Years - anyAllBeijing Anzhen Hospital
💬

In plain words

What the trial is, and whether it could suit you

Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laborator

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged ≥18 years. * Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study. * Structural heart disease diagnosed according to current clinical guidelines. * Willing and able to provide written informed consent. * Willing to comply with the study follow-up schedule. Exclusion Criteria: * Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances). * Idiopathic ventricular tachycardia without evidence of structural heart disease. * Cardiac surgery within 60 days before enrollment. * Severe infectious diseases (e.g., septic shock or sepsis). * Severe coagulation disorders, including platelet count \<50 × 10⁹/L or disseminated intravascular coagulation. * Participation in another interventional clinical study that may interfere with this registry. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation.
💊

What it tests

  • Standard Clinical Care
📍

Where

1 site
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy